webinar register page

Webinar banner
Spectradyne Webinar: Drug Delivery Vehicles at the Nanoscale - Current Best Practices For Measuring the Size and Concentration of Lipid Nanoparticles (LNPs)
Modern therapeutics increasingly use nanoparticles to deliver active ingredients. A broad range of particle types are under development for this purpose, including viruses (AAVs, Lentivirus, and many others), extracellular vesicles (EVs) and frequently liposomes and Lipid Nanoparticles (LNPs). LNPs have received particular attention recently as they carry the payload for Pfizer and Moderna’s mRNA-based COVID vaccines.

Particle concentration and size are critical attributes of these products: Particle concentration is in fact the dose, and particle size is a key determinant of the formulation’s ultimate bioavailability. These two parameters must therefore be accurately measured to ensure the safety and maximum efficacy of these therapeutics.

So what do leading-edge researchers think their LNP-based formulations look like? How are scientists in the real world measuring particle size and concentration in new nanoscale therapeutics?

Join us for a technical discussion of important considerations for accurate measurement of LNP size and concentration.

Jean-Luc Fraikin will present a brief overview of commonly used technologies for quantifying LNPs, and Lew Brown will share examples from the field that illustrate the key differences between analytical techniques including dynamic light scattering (DLS), nanoparticle tracking analysis (NTA), and microfluidic resistive pulse sensing (MRPS).

Specific Topics Covered in this Webinar:

• Technical considerations for measuring LNP size/concentration
• Review of LNP size and concentration measurement techniques
• Strengths/Weaknesses of these technologies
• Specific measurement examples with data from multiple instruments

Dec 8, 2021 01:00 PM in Eastern Time (US and Canada)

Webinar logo
* Required information
Loading

Speakers

Jean-Luc Fraikin
CEO @Spectradyne
Dr Fraikin developed the initial MRPS technology during his PhD thesis work at UC Santa Barbara in Dr. Cleland's research group. He has worked in cancer cell biology and biochemistry, and at InDevR led prototyping efforts for a microfluidics-based molecular diagnostic platform. At Spectradyne, Dr Fraikin previously led the development of instrument fluidics, software, and system integration. He is now serving as Spectradyne's CEO.
Lew Brown
Sales & Marketing @Spectradyne
Lew Brown has worked in the particle analysis market for over 15 years. Prior to working at Spectradyne, he was with Fluid Imaging Technologies as one of the first employees, serving both as Technical Director and Director of Marketing. He has been a regular speaker at industry events discussing particle analysis over the years, and has a Bachelor of Science in Imaging Science from Rochester Institute of Technology.